Fig. 3From: The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysisForest plots of the progression-free survival (PFS) for additional PARP inhibitors. a HRD mutation (p < 0.001). b no HRD mutation (p < 0.001)Back to article page